Phase I/II trial of131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma
Authors:
- Samer SuleimanSSSamer Suleiman
- David M. GoldenbergDGDavid M. Goldenberg
Open Access
Abstract
BACKGROUND Monoclonal antibodies (MAbs) against carcinoembryonic antigen (CEA) have been recognized as targeting agents for medullary thyroid carcinoma (MTC). This Phase I/II study was initiated to determine the safety, maximum tolerated dose (MTD), and therapeutic potential of 131I‐MN‐14 F(ab)2 anti‐CEA MAb for patients with metastatic MTC. METHODS Fifteen patients were enrolled in this study. Dose escalation was based on estimates of radiation dose to the bone marrow, and the radioactive dose given was determined by a pretherapy diagnostic study in which 8 mCi (0.6–20 mg) of 131I‐MN‐14 F(ab)2 was administered 1 week prior to therapy. RESULTS Three patients received an initial dose of 140 centigray (cGy) to bone marrow, 11 received 180 cGy, and 1 received 220 cGy. Myelosuppression was the only significant treatment‐related dose‐limiting toxicity (DLT), and the MTD appeared to be 180 cGy to the bone marrow. Human antimouse antibodies (HAMA) developed in 8 patients 2–6 weeks after therapy. Seven patients had a median of 55% reduction of tumor markers. One patient showed a dramatic improvement in the mass effect on the airways caused by 3 tumor lesions in the neck, with a 45% reduction of overall tumor burden. The disease has continued to be radiologically stable in 11 of 12 assessable patients for periods ranging from 3+ to 26+ months. CONCLUSIONS Therapy with 131I‐MN‐14 F(ab)2 is well tolerated and shows evidence of biochemical and radiologic antitumor activity. HAMA development suggests that humanized MAbs will be required in trials with repeated dose schedules. Further dose escalation, alone or in combination with other therapy modalities, is indicated for future trials, preferably with humanized anti‐CEA MAbs. Cancer 1999;85:1828–42. © 1999 American Cancer Society.Keywords
This publication has 10 references indexed in Scilit:
- Can occult metastases be Treated by radioimmunotherapy?Cancer, 1997
- Clinical evaluation of tumor targeting with the anticarcinoembryonic antigen murine monoclonal antibody fragment, MN-14 F(ab)2Cancer, 1996
- Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen.Journal of Clinical Oncology, 1996
- Characterization of second-generation monoclonal antibodies against carcinoembryonic antigenCancer, 1993
- Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14Cancer, 1993
- Early Diagnosis and Treatment of Medullary Thyroid CarcinomaArchives of internal medicine (1960), 1985
- External radiotherapy in thyroid cancersCancer, 1985
- Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinomaCancer, 1984
- The detection of elevated plasma levels of carcinoembryonic antigen in patients with suspected or established medullary thyroid carcinomaCancer, 1978
- Association of medullary carcinoma of the thyroid with carcinoembryonic antigenBritish Journal of Cancer, 1976